In focus

Emerging markets lag in Covid-19 vaccine race

Constraints on the supply of Covid-19 vaccines have meant that the roll-out has been much slower in  emerging markets (EM) relative to developed markets. While some EM such as Chile and those in Central Eastern Europe are distributing inoculations relatively quickly, most are lagging behind.

Despite warm words in recent weeks, the hoarding of vaccines in developed markets remains a key headwind for supply to EM. China and Russia’s efforts to build alliances by filling the vaccine vacuum with the supply of their own treatments will help some EM, particularly those that will be licensed to manufacture shots. However, the reliance on imports remains a major vulnerability for many EM, and there is a risk that these economies underperform this year.

How is vaccine distribution progressing in emerging markets?

In December we noted that while many EM economies would benefit significantly from the roll out of Covid vaccines, hopes for a rapid return to normality should be tempered. Many EM are blighted by relatively poor infrastructure and governance, while few had enough vaccines on order to immunise their populations and were relying on treatments that had not yet been proven effective and approved for use.

Unfortunately, this has so far been borne out in vaccination data.

There are some success stories. For example, as the chart below shows, as of 19 February about 15% Chile’s population had received at least one dose of vaccination, and it had inoculated an impressive 5% of the population in the previous seven days. Chile was one of the few EM that had a large amount of vaccines on order, including from suppliers such as Pfizer that were ready to be used.

Meanwhile, countries in parts of Central Eastern Europe are also faring relatively well, having vaccinated about 7% of their populations as they access European Union vaccine supplies. There has also been a positive surprise in Turkey where the rate of vaccination is accelerating.


However, most major EM countries are lagging behind in the vaccination race. As of 20 February India and Mexico had delivered a first shot of vaccine to about only 1% of their populations, while Brazil had inoculated only 3%. Even in China and Russia, which are the only two EM to have developed their own treatments, are lagging behind, albeit the data are only to 9 and 10 February respectively.

The key constraint on the roll-out of vaccines so far appears to have come from the supply of treatments. For example, Brazil started the roll-out of vaccines in January after receiving deliveries of Sinovac’s treatment from China and the Oxford/AstraZeneca vaccine that was manufactured in India. However, it had to temporarily pause distribution earlier this month after further deliveries failed to arrive.

Such delays are not particularly surprising. After all, most EM rely on imports of vaccines at a time when richer nations have hoarded treatments. At the same time, difficulties in establishing new facilities have seen manufacturers undershoot production estimates.

Vaccines: a soft power play

Supply shortages should ease as manufacturing processes are optimised and new treatments come online. However, some EM are still better placed than others and, despite recent warm words from European policymakers, vaccine nationalism remains a threat to the supply of vaccines to EM that rely on imports.

As the maps below show, China and Russia are trying to fill the vaccine vacuum left by hoarding in developed markets. These supplies could be used to build soft power across Africa, Latin America and parts of Asia.




Some EM such as Brazil and Egypt will be licensed to manufacture vaccines themselves, which could help the current pace of inoculation to accelerate in the months ahead. However, other major EM such as Mexico that continue to reply on imports of shots will remain subject to supply interruption and slow roll out.

Are vaccine laggards destined to underperform?

All other things equal, those EM that lag behind in the roll-out of vaccinations will be slow to fully re-open their economies and therefore underperform. That being said, there are nuances to the story. China and some other parts of Asia that have successfully contained Covid have been able to largely lift restrictions and these markets have performed relatively well.

At the other end of the spectrum, new Covid infections have declined in India and South Africa despite poor management of Covid and slow roll-out of vaccines. This suggests that some form of herd immunity has been reached and that these markets could perform surprisingly well.

So while the roll out of vaccines in EM merits close monitoring, they may not be the only key to macroeconomic recovery this year. 

Important Information: This communication is marketing material. The views and opinions contained herein are those of the author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds. This material is intended to be for information purposes only and is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. It is not intended to provide and should not be relied on for accounting, legal or tax advice, or investment recommendations. Reliance should not be placed on the views and information in this document when taking individual investment and/or strategic decisions. Past performance is not a reliable indicator of future results. The value of an investment can go down as well as up and is not guaranteed. All investments involve risks including the risk of possible loss of principal. Information herein is believed to be reliable but Schroders does not warrant its completeness or accuracy. Some information quoted was obtained from external sources we consider to be reliable. No responsibility can be accepted for errors of fact obtained from third parties, and this data may change with market conditions. This does not exclude any duty or liability that Schroders has to its customers under any regulatory system. Regions/ sectors shown for illustrative purposes only and should not be viewed as a recommendation to buy/sell. The opinions in this material include some forecasted views. We believe we are basing our expectations and beliefs on reasonable assumptions within the bounds of what we currently know. However, there is no guarantee than any forecasts or opinions will be realised. These views and opinions may change.  To the extent that you are in North America, this content is issued by Schroder Investment Management North America Inc., an indirect wholly owned subsidiary of Schroders plc and SEC registered adviser providing asset management products and services to clients in the US and Canada. For all other users, this content is issued by Schroder Investment Management Limited, 1 London Wall Place, London EC2Y 5AU. Registered No. 1893220 England. Authorised and regulated by the Financial Conduct Authority.